Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics Lays Off 34; Deepest Cuts in Early R&D

This story has been corrected from an earlier version that misstated the current number of Genome Therapeutics employees.


NEW YORK, Sept. 25 - Genome Therapeutics will lay off 34 of its staffers in an effort to rein in costs, the company said today. Staff will be culled from early stage R&D and from administrative support, leaving the company with 165 employees.


The move, which is expected to save Genome Therapeutics about $6 million a year, will not affect any of the revenue-producing early-research partnerhips the company has with pharma, according to a company official.


The cuts will instead focus on target-discovery research, sparing Genome Therapeutics' later-stage clinical-research and drug-development efforts.


Genome Therapeutics has a multi-year research alliance with Schering Plough to identify and characterize genes related to asthma. That partnership, scheduled to conclude at the end of 2002, brought the company $33 million through Sept. 29, 2001.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.